Enoxaparin sodium

• Target:

  Thrombin|||SARS-CoV|||Factor Xa

• Related Pathways:

  Proteases/Proteasome|||Microbiology/Virology|||Metabolism

• Bioactivity:

  Enoxaparin sodium is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention (PCI) . It binds to and potentiates the action of antithrombin, and inhibits coagulation factors XIa, IXa, Xa and IIa (thrombin), thereby preventing formation of blood clots.

• Smiles:

  [Na+].[Na+].[Na+].[Na+].C[C@@H]1[C@@H](NC(C)=O)[C@@H](OC2[C@H](O)[C@@H](O)[C@H](OC3[C@H]4CO[C@H](O4)[C@H](NS([O-])(=O)=O)[C@H]3O)OC2C([O-])=O)O[C@H](CO)[C@H]1O[C@@H]1CC([C@@H](O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]3OC(=C[C@H](O)[C@H]3O)C([O-])=O)[C@H](

• Molecular Formula:

  C42H59N3Na4O35S2

• Molecular Weight:

  1322

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C

• CAS Number:

  679809-58-6